Clinical Trial Update: A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

View source ↗

Summary

Completed clinical-trial update examining real-world adherence to and outcomes of patients with relapsing-remitting multiple sclerosis treated with ofatumumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED